文献速递肝病

鲁比前列酮降低MASLD患者MRI-PDFF脂肪含量:一项48周随机对照试验

Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial.
PubMed 文献 · Aliment Pharmacol Ther · 2025-01-02

在埃及开罗的MASLD门诊开展随机安慰剂对照试验,116例患者随机接受安慰剂或鲁比前列酮24 μg每日两次口服48周。鲁比前列酮组较安慰剂组显著降低MRI-PDFF脂肪含量(p=0.04),但两组瞬态弹性成像纤维化评分及血清ALT无显著差异;鲁比前列酮组1例出现严重腹泻需停药。

要点

  • 鲁比前列酮24 μg每日两次口服48周可显著降低MASLD患者MRI-PDFF脂肪含量(p=0.04)。
  • 两组瞬态弹性成像纤维化评分及血清ALT水平无显著差异。
  • 鲁比前列酮组1例发生严重腹泻需停药,无其他严重不良事件。

核心结论

  • 鲁比前列酮耐受性良好,在48周内降低了MASLD患者MRI-PDFF测得的肝脏脂肪含量。
  • 鲁比前列酮似乎有望用于治疗MASLD,需更广泛研究确认疗效。

研究设计与样本

  • 在埃及开罗国家肝病与热带医学研究所的专科MASLD门诊开展随机安慰剂对照试验。
  • 2020年11月至2023年2月筛查176例,116例符合条件,59例随机分入安慰剂组,57例分入鲁比前列酮组。
  • 因患者脱落(失访)为主,每组各40例获得完整数据。
  • 干预为鲁比前列酮24 μg口服每日两次,持续48周;对照为安慰剂。
  • 肝脏脂肪含量通过磁共振成像质子密度脂肪分数(MRI-PDFF)定量。

主要发现

  • 与安慰剂组相比,鲁比前列酮治疗48周显著降低脂肪量(p=0.04)。
  • 尽管对照组体重显著下降,两组间瞬态弹性成像纤维化评分无显著差异。
  • 两组间血清ALT水平无显著差异。
  • 鲁比前列酮组1例发生严重腹泻需停止治疗,无其他严重不良事件。

局限性

  • 因患者脱落(失访)为主,每组仅40例获得完整数据。
  • 鲁比前列酮似乎有望治疗MASLD,需更广泛研究确认疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The laxative lubiprostone has been shown to decrease intestinal permeability. We aimed to assess the safety and efficacy of lubiprostone administered for 48 weeks in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). APPROACH AND RESULTS: A randomised placebo-controlled trial was conducted in a specialised MASLD outpatient clinic at the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt. The recruited patients had radiological evidence of MASLD along with other criteria for diagnosis. Eligible patients were randomly assigned to receive either placebo or lubiprostone 24 μg orally twice daily for 48 weeks. The liver fat content was quantified by magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF). Between November 2020 and February 2023, 176 patients were screened, of whom 116 were eligible. Fifty-nine patients were randomised to receive placebo, while 57 patients were randomised to receive lubiprostone. Due mostly to patient dropout (i.e., loss to follow-up), complete data were available for 40 patients in each group. Compared with placebo group, 48-week lubiprostone treatment significantly reduced fat quantity (p = 0.04). Despite a significant reduction in body weight in the control group, no significant difference was found between both groups regarding fibrosis score by transient elastography or in serum ALT levels. One patient in the lubiprostone group developed severe diarrhoea requiring treatment stoppage. No other serious adverse events occurred. CONCLUSION: Lubiprostone was well tolerated and reduced liver fat content as measured by MRI-PDFF in patients with MASLD over 48 weeks. Lubiprostone appears promising to treat MASLD and warrants more extensive studies to confirm such efficacy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05768334.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. El-Kassas M, Mostafa H, Abdellatif W, et al. Lubiprostone Reduces Fat Content on MRI-PDFF in Patients With MASLD: A 48-Week Randomised Controlled Trial. Aliment Pharmacol Ther. 2025. PMID: 39744921. doi:10.1111/apt.18478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。